Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Biopharmaceutical company reports limited strong revenue growth for FY 2004
September 27th, 2004
The directors of SciGen Limited released the company's full-year financial result for fiscal year (FY) 2004. The company reported a net loss of $4.31 million, an improvement of 12% over previous year, and a revenue increase of 79% from prior year to $6.48 million. Cash receipts from are up 173% from prior year to $5.4 million, net cashflow from operating activities has improved by $2.37 million or 34% over the prior year, and cash in the bank bank at the end of the period was $9.56 million. Progress on product development and marketing include the launch of recombinant human insulin (SciLin) in Vietnam, sales of recombinant human...
Source: Obesity & Diabetes Week (2004-09-27)
|
